Merck's immunotherapy Bavencio, which was developed together with Pfizer, was found to delay the progression of kidney cancer when used in combination with Pfizer’s Inlyta drug in a late-stage study.
Durring the Phase III JAVELIN Renal 101 study, the drug combination led to longer progression-free survival in patients with advanced renal cell carcinoma (RCC) when compared with a control group on older Pfizer drug Sutent. The trial will exlpore whether Bavencio plus Inlyta also prolongs patients’ lives.
While the company said the benefit was statistically significant, they did not specify the duration of progression-free survival.
Read the full release here
[javascriptSnippet]